Recent Finacing
Recent Raise
Onena Medicines develops antibodies that modulate Dual SMAD Inhibiting Proteins, using deep-learning humanization and affinity optimization for OMED-1 (LEFTY-neutralizing) and OMED-2, conducting preclinical in vivo tumor studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
